{"product_id":"practical-cardiovascular-medicine-isbn-9781119832706","title":"Practical Cardiovascular Medicine","description":"\u003cp\u003eProviding a complete but succinct overview of the information cardiologists and cardiology trainees need to have at their fingertips, \u003ci\u003ePractical Cardiovascular Medicine, Second Edition\u003c\/i\u003e is an everyday primary guide to the specialty. \u003c\/p\u003e \u003cul\u003e \u003cli\u003eProvides cardiologists with a thorough and up-to-date review of cardiology, from pathophysiology to practical, evidence-based management \u003c\/li\u003e \u003cli\u003eAbly synthesizes pathophysiology fundamentals and evidence-based approaches to prepare a physician for a subspecialty career in cardiology \u003c\/li\u003e \u003cli\u003eClinical chapters cover coronary artery disease, heart failure, arrhythmias, valvular disorders, pericardial disorders, congenital heart disease, and peripheral arterial disease \u003c\/li\u003e \u003cli\u003ePractical chapters address ECG, coronary angiography, catheterization techniques, echocardiography, hemodynamics, and electrophysiological testing \u003c\/li\u003e \u003cli\u003eIncludes over 730 figures, key notes boxes, references for further study, and coverage of clinical trials \u003c\/li\u003e \u003cli\u003eReview questions help clarify topics and can be used for Board preparation - over 650 questions in all\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe \u003ci\u003eSecond Edition\u003c\/i\u003e has been comprehensively updated with the newest data and with both the American and European guidelines. More specifically, 20 clinical chapters have been rewritten and extensively revised. Procedural chapters have been enhanced with additional concepts and illustrations, particularly the hemodynamic and catheterization chapters. Clinical questions have been revamped, new questions have been added, including a new, 259-question section at the end of the book.  \u003c\/p\u003e \u003cp\u003e\u003ci\u003ePractical Cardiovascular Medicine, Second Edition\u003c\/i\u003e is an ideal reference for the resident, fellow, cardiologist, and any professional treating patients with cardiovascular disease. \u003c\/p\u003e \u003cp\u003ePreface xx\u003c\/p\u003e \u003cp\u003eAbbreviations xxi\u003c\/p\u003e \u003cp\u003eAbout the Companion Website xxiv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1. Coronary Artery Disease 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Non- ST- Segment Elevation Acute Coronary Syndrome 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definition types of myocardial infarction and pitfalls 1\u003c\/p\u003e \u003cp\u003eII. Clinical features ECG cardiac biomarkers and echocardiography in ACS 6\u003c\/p\u003e \u003cp\u003eIII. Initial approach to acute chest pain presentations and the use of conventional and high- sensitivity troponins 8\u003c\/p\u003e \u003cp\u003eIV. Management of NSTEMI 10\u003c\/p\u003e \u003cp\u003eV. General procedural management after coronary angiography: PCI CABG or medical therapy only 14\u003c\/p\u003e \u003cp\u003eVI. Discharge medications in NSTEMI 14\u003c\/p\u003e \u003cp\u003eVII. Prognosis 17\u003c\/p\u003e \u003cp\u003eAppendix 1. Complex angiographic disease- Moderate disease progression 17\u003c\/p\u003e \u003cp\u003eAppendix 2. Women and ACS elderly patients and ACS CKD 18\u003c\/p\u003e \u003cp\u003eAppendix 3. Bleeding transfusion patients on chronic warfarin or NOAC gastrointestinal bleed 19\u003c\/p\u003e \u003cp\u003eAppendix 4. Antiplatelet and anticoagulant therapy 20\u003c\/p\u003e \u003cp\u003eAppendix 5. Difference between plaque rupture and plaque erosion 23\u003c\/p\u003e \u003cp\u003eAppendix 6. Spontaneous coronary artery dissection 23\u003c\/p\u003e \u003cp\u003eAppendix 7. Harmful effects of NSAIDs and cyclooxygenase- 2 inhibitors in CAD 25\u003c\/p\u003e \u003cp\u003eAppendix 8. Additional ideas on the physiology of hs- troponin- Role of hs- troponin in primary prevention 25\u003c\/p\u003e \u003cp\u003eQuestions and answers 25\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. ST- Segment Elevation Myocardial Infarction 38\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Definition reperfusion and general management 39\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definition 39\u003c\/p\u003e \u003cp\u003eII. Timing of reperfusion 39\u003c\/p\u003e \u003cp\u003eIII. ECG phases of STEMI 40\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Stemi Complications 50\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Cardiogenic shock 50\u003c\/p\u003e \u003cp\u003eII. Mechanical complications 53\u003c\/p\u003e \u003cp\u003eIII. Recurrent infarction and ischemia 55\u003c\/p\u003e \u003cp\u003eAppendix 1. Out- of- hospital cardiac arrest: role of early coronary angiography and therapeutic hypothermia 60\u003c\/p\u003e \u003cp\u003eQuestions and answers 62\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Stable Ischemic Heart Disease and Approach to Chronic Chest Pain 74\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes of angina and pathophysiology of coronary flow 74\u003c\/p\u003e \u003cp\u003eII. Diagnostic approach 75\u003c\/p\u003e \u003cp\u003eIII. Silent myocardial ischemia. Is there a role for screening asymptomatic patients and post- PCI patients? 78\u003c\/p\u003e \u003cp\u003eAppendix 1. Notes on various surgical grafts 86\u003c\/p\u003e \u003cp\u003eAppendix 2. Coronary vasospasm (variant angina Prinzmetal angina) 88\u003c\/p\u003e \u003cp\u003eAppendix 3. Microvascular endothelial dysfunction 90\u003c\/p\u003e \u003cp\u003eAppendix 4. Women with chest pain and normal coronary arteries 90\u003c\/p\u003e \u003cp\u003eAppendix 5. Diagnostic strategy for ischemia with non- obstructed coronary arteries (INOCA) 91\u003c\/p\u003e \u003cp\u003eAppendix 6. Myocardial bridging 91\u003c\/p\u003e \u003cp\u003eAppendix 7. Coronary collaterals chronic total occlusion 92\u003c\/p\u003e \u003cp\u003eAppendix 8. Hibernation stunning ischemic preconditioning 92\u003c\/p\u003e \u003cp\u003eQuestions and answers 93\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2. Heart Failure (Chronic and Acute Heart Failure Specific Cardiomyopathies and Pathophysiology) 103\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Heart Failure 103\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDefinition Types Causes and Diagnosis of Heart Failure 104\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Definition and types of heart failure 104\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Heart failure is diagnosed clinically not by echocardiography 104\u003c\/p\u003e \u003cp\u003eII. After HF is defined clinically echocardiography is used to differentiate the three major types of HF 105\u003c\/p\u003e \u003cp\u003eIII. Two additional types of HF 107\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Causes of heart failure 107\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Systolic HF or HF with reduced EF (HFrEF) 107\u003c\/p\u003e \u003cp\u003eII. HF with preserved EF (HFpEF) 108\u003c\/p\u003e \u003cp\u003eIII. Right HF 110\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Diagnostic tests 110\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Echocardiography 110\u003c\/p\u003e \u003cp\u003eII. BNP 111\u003c\/p\u003e \u003cp\u003eIII. ECG 112\u003c\/p\u003e \u003cp\u003eIV. Coronary angiography and other ischemic tests 112\u003c\/p\u003e \u003cp\u003eChronic Treatment of Heart Failure 113\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Treatment of systolic heart failure 113\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Treat the underlying etiology: target BP and CAD 113\u003c\/p\u003e \u003cp\u003eII. Value of revascularization in ischemic cardiomyopathy: STICH trial 113\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Treatment of HFpEF 124\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAcute Heart Failure and Acutely Decompensated Heart Failure 126\u003c\/p\u003e \u003cp\u003eI. Triggers of acute decompensation 126\u003c\/p\u003e \u003cp\u003eII. Profiles of acute HF: congestion without low cardiac output congestion with low cardiac output 127\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAppendix 1. Management of isolated or predominant RV failure 135\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eQuestions and answers 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Additional Heart Failure Topics 156\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Specific cardiomyopathies 156\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Arrhythmia- induced cardiomyopathy 156\u003c\/p\u003e \u003cp\u003eII. Viral myocarditis 157\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Advanced heart failure: heart transplant and ventricular assist devices 163\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Stages of HF 163\u003c\/p\u003e \u003cp\u003eII. Cardiac transplantation 163\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Pathophysiology of heart failure and hemodynamic aspects 166\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. LV diastolic pressure in normal conditions and in HF (whether systolic or diastolic) 166\u003c\/p\u003e \u003cp\u003eII. Definition of afterload 167\u003c\/p\u003e \u003cp\u003eQuestions and answers 173\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3. Valvular Disorders 181\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Valvular Disorders 181\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Mitral regurgitation 182\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Mechanisms of mitral regurgitation 182\u003c\/p\u003e \u003cp\u003eII. Specifics of various causes of mitral regurgitation 182\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Mitral stenosis 192\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Etiology and natural history 192\u003c\/p\u003e \u003cp\u003eII. Diagnosis 193\u003c\/p\u003e \u003cp\u003eIII. Treatment 197\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Aortic insufficiency 199\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Etiology 199\u003c\/p\u003e \u003cp\u003eII. Pathophysiology and hemodynamics 200\u003c\/p\u003e \u003cp\u003eIII. Diagnosis 200\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Aortic stenosis 203\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Etiology 203\u003c\/p\u003e \u003cp\u003eII. Echo and catheterization diagnosis pitfalls and hemodynamics 204\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Tricuspid regurgitation and stenosis 213\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Etiology of tricuspid regurgitation 213\u003c\/p\u003e \u003cp\u003eII. Natural history of TR 215\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Pulmonic stenosis and regurgitation 216\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Pulmonic stenosis 216\u003c\/p\u003e \u003cp\u003eII. Pulmonic regurgitation 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Mixed valvular disease; radiation heart disease 217\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Mixed single- valve disease 217\u003c\/p\u003e \u003cp\u003eII. Multiple valvular involvement (combined stenosis or regurgitation of two different valves) 217\u003c\/p\u003e \u003cp\u003eIII. Radiation heart disease 217\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Prosthetic valves 218\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Bioprosthesis versus mechanical prosthesis 218\u003c\/p\u003e \u003cp\u003eII. Determinants of valve degeneration and valve thrombosis; anticoagulation guidelines 218\u003c\/p\u003e \u003cp\u003eIII. Particular cases: women who wish to become pregnant and dialysis patients 220\u003c\/p\u003e \u003cp\u003eIV. Echocardiographic follow- up of prosthetic valves 221\u003c\/p\u003e \u003cp\u003eV. Complications 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Auscultation and summary ideas 223\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Auscultation and other physical findings 223\u003c\/p\u003e \u003cp\u003eII. General ideas and workup 226\u003c\/p\u003e \u003cp\u003eQuestions and answers 227\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4. Hypertrophic Cardiomyopathy 243\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Hypertrophic Cardiomyopathy 243\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definition and features of HCM 243\u003c\/p\u003e \u003cp\u003eII. Natural history and mortality 245\u003c\/p\u003e \u003cp\u003eIII. Symptoms and ECG 246\u003c\/p\u003e \u003cp\u003eQuestions and answers 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5. Arrhythmias and Electrophysiology 257\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Approach to Narrow and Wide QRS Complex Tachyarrhythmias 257\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. The unstable patient 257\u003c\/p\u003e \u003cp\u003eII. Initial approach to any tachycardia 257\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Ventricular Arrhythmias: Types and Management Sudden Cardiac Death 274\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Premature ventricular complexes 274\u003c\/p\u003e \u003cp\u003eII. Ventricular tachycardia 276\u003c\/p\u003e \u003cp\u003eIII. Polymorphic ventricular tachycardia 278\u003c\/p\u003e \u003cp\u003eQuestions and answers 288\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. Atrial Fibrillation 294\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Predisposing factors 294\u003c\/p\u003e \u003cp\u003eII. Types of AF 295\u003c\/p\u003e \u003cp\u003eIII. General therapy of AF 295\u003c\/p\u003e \u003cp\u003eX. AF burden as a correlate and a driver of HF progression 303\u003c\/p\u003e \u003cp\u003eAppendix 1. Optimal heart rate and AF rate for optimal cardiac output 303\u003c\/p\u003e \u003cp\u003eAppendix 2. Antiarrhythmic drug therapy 303\u003c\/p\u003e \u003cp\u003eAppendix 3. Catheter ablation of atrial fibrillation surgical ablation AV nodal ablation 305\u003c\/p\u003e \u003cp\u003eAppendix 4. INR follow- up in patients receiving warfarin- Non- vitamin K oral anticoagulants 306\u003c\/p\u003e \u003cp\u003eAppendix 5. Bridging anticoagulation in patients undergoing procedures 308\u003c\/p\u003e \u003cp\u003eAppendix 6. Management of elevated INR values 309\u003c\/p\u003e \u003cp\u003eAppendix 7. Left atrial appendage surgical and percutaneous closure 309\u003c\/p\u003e \u003cp\u003eAppendix 8. A common situation: AF and symptomatic pauses or bradycardia 309\u003c\/p\u003e \u003cp\u003eAppendix 9. DC cardioversion in patients with a slow ventricular response 310\u003c\/p\u003e \u003cp\u003eAppendix 10. AF occurring post- cardiac surgery and AF related to acute transient triggers 310\u003c\/p\u003e \u003cp\u003eAppendix 11. Brief asymptomatic runs of AF on device interrogation and association with stroke. Role of rhythm monitoring after cryptogenic stroke 310\u003c\/p\u003e \u003cp\u003eQuestions and answers 311\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. Atrial Flutter and Atrial Tachycardia 319\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Atrial flutter 319\u003c\/p\u003e \u003cp\u003eII. Focal atrial tachycardia 322\u003c\/p\u003e \u003cp\u003eIII. Multifocal atrial tachycardia (MAT) (or chaotic atrial tachycardia) 325\u003c\/p\u003e \u003cp\u003eQuestions and answers 326\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. Atrioventricular Nodal Reentrant Tachycardia Atrioventricular Reciprocating Tachycardia Wolff–Parkinson– White Syndrome and Junctional Rhythms 329\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Inappropriate sinus tachycardia (IST) and postural orthostatic tachycardia syndrome (POTS) 329\u003c\/p\u003e \u003cp\u003eII. Atrioventricular nodal reentrant tachycardia (AVNRT) 329\u003c\/p\u003e \u003cp\u003eIII. Atrioventricular reciprocating tachycardia (AVRT) and Wolff–Parkinson–White (WPW) syndrome 332\u003c\/p\u003e \u003cp\u003eQuestions and answers 342\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13. Bradyarrhythmias 345\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. AV block 345\u003c\/p\u003e \u003cp\u003eII. Sinus node dysfunction 354\u003c\/p\u003e \u003cp\u003eQuestions and answers 359\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14. Permanent Pacemaker and Implantable Cardioverter Defibrillator 363\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Indications for permanent pacemaker implantation 363\u003c\/p\u003e \u003cp\u003eII. Types of cardiac rhythm devices 363\u003c\/p\u003e \u003cp\u003eAppendix. Cases of PM troubleshooting 381\u003c\/p\u003e \u003cp\u003eQuestions and answers 386\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15. Basic Electrophysiologic Study 390\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. General concepts; intracardiac electrograms 390\u003c\/p\u003e \u003cp\u003eII. AV conduction abnormalities 390\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16. Action Potential Features and Propagation: Mechanisms of Arrhythmias Antiarrhythmic Drugs 403\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Action potential 403\u003c\/p\u003e \u003cp\u003eII. Action potential propagation and mechanisms of arrhythmias 403\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6. Pericardial Disorders 411\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17. Pericardial Disorders 411\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Acute pericarditis 412\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes of acute pericarditis 412\u003c\/p\u003e \u003cp\u003eII. History and physical findings 412\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Tamponade 414\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definition 414\u003c\/p\u003e \u003cp\u003eII. Pathophysiology and hemodynamics 414\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Pericardial effusion 417\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes of a pericardial effusion with or without tamponade 417\u003c\/p\u003e \u003cp\u003eII. Management of asymptomatic effusions and role of pericardiocentesis 418\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Constrictive pericarditis 421\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes 421\u003c\/p\u003e \u003cp\u003eII. Pathophysiology and hemodynamics 421\u003c\/p\u003e \u003cp\u003eQuestions and answers 429\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7. Congenital Heart Disease 435\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18. Congenital Heart Disease 435\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Acyanotic congenital heart disease 435\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Atrial septal defect (ASD) 435\u003c\/p\u003e \u003cp\u003eII. Patent foramen ovale (PFO) 439\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Cyanotic congenital heart disease 444\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Pulmonary hypertension secondary to shunt 444\u003c\/p\u003e \u003cp\u003eII. Tetralogy of Fallot 445\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. More complex cyanotic congenital heart disease and shunt procedures 447\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Functionally single ventricle and Fontan procedure 447\u003c\/p\u003e \u003cp\u003eII. Transposition of great arteries (TGA) 449\u003c\/p\u003e \u003cp\u003eQuestions and answers 452\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8. Peripheral Arterial Disease 457\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19. Peripheral Arterial Disease 457\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Lower extremity peripheral arterial disease 457\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Clinical tips 458\u003c\/p\u003e \u003cp\u003eII. Clinical classification of PAD: critical limb ischemia acute limb ischemia atheroembolization 459\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Carotid disease 466\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Assessment of carotid stenosis 466\u003c\/p\u003e \u003cp\u003eII. Medical therapy of carotid stenosis 467\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Renal artery stenosis 469\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Forms of renal artery stenosis 469\u003c\/p\u003e \u003cp\u003eII. Screening and indications to revascularize renal artery stenosis 469\u003c\/p\u003e \u003cp\u003eIII. Notes 470\u003c\/p\u003e \u003cp\u003eQuestions and answers 470\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20. Aortic Diseases 476\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Aortic dissection 476\u003c\/p\u003e \u003cp\u003eII. Thoracic aortic aneurysm 480\u003c\/p\u003e \u003cp\u003eIII. Abdominal aortic aneurysm 484\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9. Other Cardiovascular Disease States 487\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21. Pulmonary Embolism and Deep Vein Thrombosis 487\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Pulmonary embolism 487\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Presentation of pulmonary embolism and risk factors 487\u003c\/p\u003e \u003cp\u003eII. Probability of PE 488\u003c\/p\u003e \u003cp\u003eIII. Initial workup 488\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Deep vein thrombosis 494\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Types 494\u003c\/p\u003e \u003cp\u003eII. Diagnosis 494\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Immune heparin- induced thrombocytopenia 494\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Incidence 495\u003c\/p\u003e \u003cp\u003eII. Diagnosis 495\u003c\/p\u003e \u003cp\u003eQuestions and answers 495\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22. Shock and Fluid Responsiveness 499\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Shock 499\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Shock definition and mechanisms 499\u003c\/p\u003e \u003cp\u003eII. Goals of shock treatment 500\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Fluid Responsiveness 503\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAppendix. Hemodynamic equations transfusion and miscellaneous concepts 505\u003c\/p\u003e \u003cp\u003eQuestions and answers 507\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23. Hypertension 511\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Hypertension 511\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definition 511\u003c\/p\u003e \u003cp\u003eII. ACC and ESC targets of therapy and rationale 512\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Acute severe hypertension: hypertensive emergencies and urgencies 521\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definitions 521\u003c\/p\u003e \u003cp\u003eII. Treatment of hypertensive emergencies 521\u003c\/p\u003e \u003cp\u003eQuestions and answers 523\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24. Dyslipidemia 529\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Indications for therapy 529\u003c\/p\u003e \u003cp\u003eII. Notes on LDL HDL and triglycerides 530\u003c\/p\u003e \u003cp\u003eQuestions and answers 534\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25. Pulmonary Hypertension 538\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Definition 538\u003c\/p\u003e \u003cp\u003eII. Categories of PH 538\u003c\/p\u003e \u003cp\u003eQuestions and answers 543\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26. Syncope 547\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Neurally mediated syncope (reflex syncope) 547\u003c\/p\u003e \u003cp\u003eII. Orthostatic hypotension and postural orthostatic tachycardia syndrome 548\u003c\/p\u003e \u003cp\u003eIII. Cardiac syncope 549\u003c\/p\u003e \u003cp\u003eQuestions and answers 556\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27. Chest Pain Dyspnea Palpitations 561\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Chest Pain 561\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes 561\u003c\/p\u003e \u003cp\u003eII. Features 562\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Acute Dyspnea 564\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes 564\u003c\/p\u003e \u003cp\u003eII. Notes 565\u003c\/p\u003e \u003cp\u003eIII. Management 566\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Palpitations 567\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Causes 567\u003c\/p\u003e \u003cp\u003eII. Diagnosis 567\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28. Infective Endocarditis and Cardiac Rhythm Device Infections 570\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Infective endocarditis 570\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Clinical diagnosis 570\u003c\/p\u003e \u003cp\u003eII. Echocardiography: timing and indications 570\u003c\/p\u003e \u003cp\u003eIII. Organisms 571\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Cardiac rhythm device infections 574\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Organisms and mechanisms of infection 574\u003c\/p\u003e \u003cp\u003eII. Diagnosis 574\u003c\/p\u003e \u003cp\u003e\u003cb\u003e29. Preoperative Cardiac Evaluation 577\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Steps in preoperative evaluation 578\u003c\/p\u003e \u003cp\u003eII. Surgical risk: surgery’s risk and patient’s risk 578\u003c\/p\u003e \u003cp\u003eIII. CARP and DECREASE V trials 579\u003c\/p\u003e \u003cp\u003eQuestions and answers 581\u003c\/p\u003e \u003cp\u003e\u003cb\u003e30. Miscellaneous Cardiac Topics: Cardiac Masses and Tumors Pregnancy HIV and Heart Disease Cocaine and the Heart Chemotherapy and Heart Disease Chest X‐Ray 584\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Cardiac masses 585\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Differential diagnosis of a cardiac mass 585\u003c\/p\u003e \u003cp\u003eII. Cardiac tumors; focus on atrial myxoma 585\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Pregnancy and heart disease 586\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. High‐risk cardiac conditions during which pregnancy is better avoided 587\u003c\/p\u003e \u003cp\u003eII. Cardiac conditions that are usually well tolerated during pregnancy but in which careful cardiac evaluation and clinical and echo follow‐up are warranted 587\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. HIV and heart disease 590\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Pericardial disease 590\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Cocaine and the heart 590\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Myocardial ischemia 590\u003c\/p\u003e \u003cp\u003eII. Other cardiac complications of cocaine 591\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Chemotherapy and heart disease 591\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Cardiomyopathy 591\u003c\/p\u003e \u003cp\u003eII. Myocardial ischemia 592\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Chest X‐ray 593\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Chest X‐ray in heart failure 593\u003c\/p\u003e \u003cp\u003eII. Various forms of cardiomegaly 594\u003c\/p\u003e \u003cp\u003eQuestions and answers 596\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 10. Cardiac Tests: Electrocardiography Echocardiography and Stress Testing 601\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e31. Electrocardiography 601\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Overview of ECG leads and QRS morphology 601\u003c\/p\u003e \u003cp\u003eII. Stepwise approach to ECG interpretation 604\u003c\/p\u003e \u003cp\u003eIII. Rhythm and rate 605\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAppendix 1. Supplement on STEMI and Q‐wave MI: phases and localization 653\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAppendix 2. Spread of electrical depolarization in various disease states using vector illustration 658\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eQuestions and answers 659\u003c\/p\u003e \u003cp\u003e\u003cb\u003e32. Echocardiography 666\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. General echocardiography 666\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. The five major echocardiographic views and the myocardial wall segments 666\u003c\/p\u003e \u003cp\u003eII. Global echo assessment of cardiac function and structure 666\u003c\/p\u003e \u003cp\u003eIII. Doppler and assessment of valvular regurgitation and stenosis 676\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Transesophageal echocardiography (TEE) views 703\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAppendix. Note on LV mechanics and myocardial tissue strain 713\u003c\/p\u003e \u003cp\u003e\u003cb\u003e33. Stress Testing Nuclear Imaging Coronary CT Angiography cardiac MRI cardiopulmonary exercise testing 714\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Indications for stress testing 714\u003c\/p\u003e \u003cp\u003eII. Contraindications to all stress testing modalities 715\u003c\/p\u003e \u003cp\u003eIII. Stress testing modalities 715\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 11 Cardiac Tests: Invasive Coronary and Cardiac Procedures 733\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e34. Angiographic Views: Coronary Arteries and Grafts Left Ventricle Aorta Coronary Anomalies Peripheral Arteries Carotid Arteries 733\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Right coronary artery 733\u003c\/p\u003e \u003cp\u003eII. Left coronary artery 734\u003c\/p\u003e \u003cp\u003eIII. Coronary angiography views. Recognize the angle of a view: LAO vs. RAO cranial vs. caudal 735\u003c\/p\u003e \u003cp\u003eQuestions and answers 765\u003c\/p\u003e \u003cp\u003e\u003cb\u003e35. Cardiac Catheterization Techniques Tips and Tricks 768\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. View for the engagement of the native coronary arteries: RAO vs. LAO 768\u003c\/p\u003e \u003cp\u003eII. Design of the Judkins and Amplatz catheters 768\u003c\/p\u003e \u003cp\u003eIII. Engagement of the RCA 768\u003c\/p\u003e \u003cp\u003e\u003cb\u003e36. Hemodynamics 790\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Right heart catheter 790\u003c\/p\u003e \u003cp\u003eII. Overview of pressure tracings: differences between atrial ventricular and arterial tracings 790\u003c\/p\u003e \u003cp\u003eIII. RA pressure abnormalities 790\u003c\/p\u003e \u003cp\u003eAppendix 1. Advanced hemodynamic calculation: a case of shunt with pulmonary hypertension 808\u003c\/p\u003e \u003cp\u003eQuestions and answers: Additional hemodynamic cases 809\u003c\/p\u003e \u003cp\u003e\u003cb\u003e37. Intracoronary Imaging 815\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Intravascular ultrasound (IVUS) 815\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Image basics 815\u003c\/p\u003e \u003cp\u003eII. Plaque types 818\u003c\/p\u003e \u003cp\u003e2. Optical coherence tomography (OCT) 823\u003c\/p\u003e \u003cp\u003e\u003cb\u003e38. Percutaneous Coronary Interventions and Complications Intra‐Aortic Balloon Pump Ventricular Assist Devices and Fractional Flow Reserve 826\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. Major coronary interventional devices 826\u003c\/p\u003e \u003cp\u003eII. Stent thrombosis restenosis and neoatherosclerosis 828\u003c\/p\u003e \u003cp\u003eIII. Peri‐PCI antithrombotic therapy 830\u003c\/p\u003e \u003cp\u003eQuestions and answers 845\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAppendix: General review questions 851\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Questions 851\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eI. NSTEMI and STEMI 851\u003c\/p\u003e \u003cp\u003eII. Stable CAD 855\u003c\/p\u003e \u003cp\u003eIII. Heart failure and cardiomyopathies 858\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Answers 901\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIndex 931\u003c\/p\u003e \u003cp\u003e\u003cb\u003eElias B. Hanna, MD,\u003c\/b\u003e is Associate Professor of Medicine (Cardiovascular Medicine and Interventional Cardiology) at the University of Iowa. He has authored multiple cardiology books and has extensive fellowship teaching experience.\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePractical Cardiovascular Medicine\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eProviding a complete but succinct overview of the information cardiologists and cardiology trainees need to have at their fingertips, \u003ci\u003ePractical Cardiovascular Medicine, Second Edition\u003c\/i\u003e is an everyday primary guide to the specialty.  \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e Provides cardiologists with a thorough and up-to-date review of cardiology, from pathophysiology to practical, evidence-based management\u003c\/li\u003e \u003cli\u003e Ably synthesizes pathophysiology fundamentals and evidence-based approaches to  prepare a physician for a subspecialty career in cardiology \u003c\/li\u003e \u003cli\u003e Clinical chapters cover coronary artery disease, heart failure, arrhythmias, valvular disorders, pericardial disorders, congenital heart disease, and peripheral arterial disease\u003c\/li\u003e \u003cli\u003ePractical chapters address ECG, coronary angiography, catheterization techniques, echocardiography, hemodynamics, and electrophysiological testing\u003c\/li\u003e \u003cli\u003e Includes over 730 figures, key notes boxes, references for further study, and coverage of clinical trials\u003c\/li\u003e \u003cli\u003eReview questions help clarify topics and can be used for Board preparation - over 650 questions in all!\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eThe second edition has been comprehensively updated with the newest data and with both the American and European guidelines. More specifically, 20 clinical chapters have been rewritten and extensively revised. Procedural chapters have been enhanced with additional concepts and illustrations, particularly the hemodynamic and catheterization chapters. Clinical questions have been revamped, new questions have been added, including a new, 259-question section at the end of the book. \u003c\/p\u003e\u003cp\u003e\u003ci\u003ePractical Cardiovascular Medicine, Second Edition \u003c\/i\u003eis an ideal reference for the resident, fellow, cardiologist, and any professional treating patients with cardiovascular disease.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989829075173,"sku":"NP9781119832706","price":139.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119832706.jpg?v=1761785604","url":"https:\/\/k12savings.com\/products\/practical-cardiovascular-medicine-isbn-9781119832706","provider":"K12savings","version":"1.0","type":"link"}